Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of new data with vamorolone in Duchenne muscular dystrophy (DMD). Cross-study comparisons of long-term efficacy, impact on growth velocity, and frequency and severity of spinal fractures for vamorolone versus current standard of care from the Phase 2b VISION-DMD study and the FOR-DMD study will be presented during the poster session at the 2022 Annual Conference of Parent Project Muscular Dystrophy (PPMD) to be held from June 23-26, 2022, in Scottsdale, AZ, USA....